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Background: Cell adhesion molecules (CAMs) are expressed ubiquitously. Each of the four families of CAMs is
comprised of glycosylated, membrane-bound proteins that participate in multiple cellular processes including cell-
cell communication, cell motility, inside-out and outside-in signaling, tumorigenesis, angiogenesis and metastasis.
Intercellular adhesion molecule-2 (ICAM-2), a member of the immunoglobulin superfamily of CAMs, has six N-linked
glycosylation sites at amino acids (asparagines) 47, 82, 105, 153, 178 and 187. Recently, we demonstrated a
previously unknown function for ICAM-2 in tumor cells. We showed that ICAM-2 suppressed neuroblastoma cell
motility and growth in soft agar, and induced a juxtamembrane distribution of F-actin in vitro. We also showed that
ICAM-2 completely suppressed development of disseminated tumors in vivo in a murine model of metastatic NB.
These effects of ICAM-2 on NB cell phenotype in vitro and in vivo depended on the interaction of ICAM-2 with the
cytoskeletal linker protein α-actinin. Interestingly, ICAM-2 did not suppress subcutaneous growth of tumors in mice,
suggesting that ICAM-2 affects the metastatic but not the tumorigenic potential of NB cells. The goal of the study
presented here was to determine if the glycosylation status of ICAM-2 influenced its function in neuroblastoma cells.
Methods: Because it is well documented that glycosylation facilitates essential steps in tumor progression and
metastasis, we investigated whether the glycosylation status of ICAM-2 affected the phenotype of NB cells. We used
site-directed mutagenesis to express hypo- or non-glycosylated variants of ICAM-2, by substituting alanine for
asparagine at glycosylation sites, and compared the impact of each variant on NB cell motility, anchorage-independent
growth, interaction with intracellular proteins, effect on F-actin distribution and metastatic potential in vivo.
Results: The in vitro and in vivo phenotypes of cells expressing glycosylation site variants differed from cells expressing
fully-glycosylated ICAM-2 or no ICAM-2. Most striking was the finding that mice injected intravenously with NB cells
expressing glycosylation site variants survived longer (P ≤ 0.002) than mice receiving SK-N-AS cells with undetectable
ICAM-2. However, unlike fully-glycosylated ICAM-2, glycosylation site variants did not completely suppress disseminated
tumor development.
Conclusions: Reduced glycosylation of ICAM-2 significantly attenuated, but did not abolish, its ability to suppress
metastatic properties of NB cells.
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Cell adhesion molecules (CAMs) participate in diverse
functions in normal cells and tumor cells. These func-
tions include cell-cell and cell-matrix adhesion, migra-
tion, oncogenesis, metastasis, tumor suppression or
progression, and signal transduction [1-5]. Based on
known functions, four major families of CAMs have
been identified: integrins, cadherins, selectins, and im-
munoglobulin (Ig) superfamily. CAMs of the Ig super-
family contain one or more domains similar to the C2
type domains characteristic of a subset of Ig molecules
(immunoglobulin-like C2 domain [IgLD]) [6].
Intercellular adhesion molecule-2 (ICAM-2), a 55-60
kDa transmembrane glycoprotein, belongs to the Ig
superfamily of CAMs [7,8]. In normal tissue, neovascular
endothelial cells express the highest level of ICAM-2.
Established vasculature and some leukocytes express a
relatively low level of ICAM-2. Functionally, the extra-
cellular domain (ED) of ICAM-2 mediates binding ofICAM-2
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Figure 1 Schematic structure of ICAM-2 and ICAM-2 variants. Schematic
glycosylation site variants (gsv). ICAM-2 wild type (WT) contains six glycosylate
176 and 187. The ED also contains two immunoglobulin-like domains (design
domains are also present. The N-terminus of the nascent protein contains a 2
mature protein. Variants were constructed by substituting alanines (A) for asp
contains alanines at mutation sites 1, 4, and 5 (amino acids 47, 153, and 176);
Variant gsv1-6 has alanines at all six glycosylation sites, and is non-glycosylateICAM-2 on vascular endothelial cells to β2-integrins on
the surface of leukocytes, an initial step in immune re-
sponses [9,10]. ICAM-2 also facilitates neutrophil bind-
ing to and migration through vascular endothelium as a
component of immune reactions [11,12]. In tumor cells,
we recently identified a unique role for ICAM-2 when
we demonstrated that ICAM-2 suppressed the meta-
static phenotype neuroblastoma (NB) cells [13].
Structurally, ICAM-2 wild type (WT) protein in nor-
mal cells [14] and NB cells is identical (Figure 1). ICAM-2
WT is expressed as a 275-amino acid protein containing
two Ig-like domains (IgLD-1 and IgLD-2) in the extracel-
lular domain (ED) at the N-terminus of the protein, a 26-
amino acid transmembrane domain (TD), and a 26-amino
acid cytoplasmic domain (CD). The first 21 amino acids
comprise a signal peptide (sp) that routes the nascent
protein through the endoplasmic reticulum, for post-
translational processing. Processing includes deletion of
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representation of the structures of ICAM-2 and hypo-glycosylated ICAM-2
d amino acids in its extracellular domain (ED), at residues 47, 82, 105, 153,
ated IgLD-1 and -2). Short transmembrane (TD) and cytoplasmic (CD)
1-amino acid signal peptide (sp) that is not present in the 254 amino acid
aragines (N) at the indicated amino acid residues. For example, gsv1,4,5
therefore, gsv1,4,5 is not able to be glycosylated at these three sites.
d when expressed in SK-N-AS cell transfectants.
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the TD and CD noted above. The CD binds to actin cyto-
skeletal linker ERM proteins (ezrin, radixin, moesin) and
to α-actinin [15,16]. The functional significance of the in-
teractions of ICAM-2 with actin linker proteins in tumor
cells is largely unknown, with the exception of our recent
observation that the interaction of ICAM-2 with α-actinin
is essential to ICAM-2-mediated suppression of the meta-
static potential of NB cells [13].
The ED of ICAM-2 contains six N-glycosylation sites
(asparagines [Asn] residues; amino acids # 47, 82, 105,
153, 178 and 187) [17], a frequent post translational modi-
fication of CAM proteins and a modification known, in
general, to influence CAM structure and function and to
impact the phenotype of tumor cells [18-20]. For example,
altered N-glycosylation of β1-integrin decreases cell mi-
gration [21], and aberrant N-glycosylation of E-cadherin
increases discohesion of oral cancer cells [22]. The effect
of glycosylation of ICAM-2 on tumor cell function is
unknown.
Our previous studies, however, document that fully
glycosylated ICAM-2 suppresses the development of dis-
seminated tumors in a murine model of metastatic NB.
Importantly, and consistent with preclinical data, we also
showed that primary human NB cells that express en-
dogenous ICAM-2 have morphologic and histologic
properties of NB cells recognized clinically to have lim-
ited metastatic potential [13]. These observations sug-
gest a functional role for ICAM-2 in primary tumor
cells. Therefore, in order to identify domains of ICAM-2
that contribute significantly to its function in tumor
cells, we generated four ICAM-2 constructs, encoding
glycosylation site variants (gsv) of this protein. We
expressed each construct in SK-N-AS NB cells, which
have no detectable endogenous ICAM-2 and which dis-
play a metastatic phenotype in in vitro assays and in vivo
models. We altered the glycosylation status of ICAM-2
by substitution of alanines for asparagines, to prevent
glycosylation at specific residues that comprise N-linked
glycosylation sites in situ; and then determined whether
substitutions modulated the ability of ICAM-2 to sup-
press metastatic properties of NB cells. The data show
that hypo-glycosylated variants of ICAM-2 have a sig-
nificant impact on NB cell phenotype, but to a lesser ex-
tent than that seen with ICAM-2 WT.
Methods
Cell lines and culture conditions
The human neuroblastoma (NB) cell line SK-N-AS
(American Type Culture Collection, Manassas, VA) was
maintained in Dulbecco's Modified Eagle Medium
(DMEM; Hyclone, Fisher Scientific, Savannah, GA) with
10% fetal bovine serum (Atlanta Biologicals, Lawrenceville,
GA) and 2 mM L-glutamine (Hyclone, Fisher Scientific,Savannah, GA) at 37°C and 10% CO2. Parent SK-N-AS
cells and stable transfectants were cultured under the
same conditions. Human dermal microvascular endothe-
lial cells (HDMVEC) were obtained from Lonza, Inc.
(Allendale, NJ), and the human bone marrow endothelial
cell line, HBMEC-28, was provided by Dr. E. van der Schoot
(Sanquin Blood Supply Foundation, The Netherlands) [23].
HDMVEC cells were grown in gelatin-coated culture
flasks in Endothelial Cell Grown Medium (EGM) sup-
plemented with 10% heat-inactivated FBS. HBMEC-28
cells were propagated in medium prepared using the
EGM™ BulletKit™ (Lonza) according to the directions of
the manufacturer.
Plasmids encoding human ICAM-2 and ICAM-2 variants
The plasmid encoding human ICAM-2 was generated as
published [13]. Briefly, cDNA encoding ICAM-2 was
generated from RNA isolated from human umbilical vein
endothelial cells (Clonetics, San Diego, CA). Primers for
full length ICAM-2 were: forward (5'GCTTCCGCTGCC
TGGATTCT3') and reverse (5'AAGTCCAGGTGTTGTA
TTC3'). Amplification was performed at 95°C for 1 min;
then 30 cycles of 94°C for 30 sec, 55°C for 30 sec, 72°C for
1 min, followed by 72°C for 7 min. The resulting cDNA
was isolated after electrophoresis in agarose gels, se-
quenced in its entirety by automated sequencing methods
(St. Jude Hartwell Center for Bioinformatics, Memphis,
TN), and subcloned into the BamH1 restriction site of the
expression plasmid pIRESneo2 (Clontech, San Jose, CA)
to generate pIRES.ICAM-2. Plasmid transfections were
carried out using FuGene6 (Roche Diagnostics, Indianapo-
lis, IN). Forty-eight hours after transfection, 750 μg/ml
geneticin (G418; Roche Diagnostics Corporation, Indian-
apolis, IN) was added to select transfected cell popula-
tions. The use of a vector containing an internal ribosomal
entry site (IRES) between the ICAM-2 cDNA and the
gene encoding the G418 resistance protein eliminated the
need to isolate and characterize multiple individual clonal
cell lines. The ICAM-2 cDNA sequence was verified as
error-free in the resulting cell line (SK-N-ASpIRES.ICAM-
2) by the St. Jude Hartwell Center.
Mutagenesis and nomenclature of ICAM-2 variants
The objective of this study was to evaluate the impact of
the glycosylation status of ICAM-2 on the function in
NB tumor cells. Therefore, mutagenesis by overlapping
PCR, using Pfu polymerase (QuickChange mutagenesis
kit; Stratagene-Agilent Tech, Wilmington, DE) and
pIRES.ICAM-2 as a template, was performed to replace
some or all of the six asparagine glycosylation sites with
alanine residues at positions 47, 82, 105, 153, 176, and
187, each of which is glycosylated in the endogenous
wild-type protein. Alanine was chosen for substitution at
all six or of a subset of glycosylation sites to prevent
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of ICAM-2 cDNA were identified by restriction enzyme
analysis and sequences confirmed by direct DNA sequen-
cing. Transfection of plasmids encoding ICAM-2 variants
into SK-N-AS cells, selection of transfected cells, and cul-
ture conditions were the same as for SK-N-ASpIRES.
ICAM-2 transfectants. Plasmids and transfected cell lines
are designated as glycosylation site variants (gsv) followed
by the positions of the amino acids (asparagines) that were
replaced with alanine. For example, gsv1,4,5 is non-
glycosylated at amino acids 47, 153 and 176 (Figure 1). In
Figures 2, 3, 4, 5, 6, 7 and 8, transfected SK-N-AS cell lines
expressing variant forms of ICAM-2 are referred to as the
specific variant expressed: gsv1,4,5; gsv1,2,5; gsv4,5; and
gsv1-6. SK-N-AS cells expressing ICAM-2 WT are labeled
in the Figures as “WT”. SK-N-ASpIRESneo2 control
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Figure 2 Transfected SK-N-AS cells express ICAM-2 transcripts and pr
cells (HDMVEC) generated RT-PCR products of the predicted 631 base pairs
B) Bar graph depicting quantitation of the RT-PCR products shown in “A”.
level of variability was not statistically significant. C) Immunoblots of whole
cells and WT transfectants expressed immunoreactive protein having an ap
proteins of appropriately lesser apparent masses. Transfectants expressed
in whole cell lysates and subsequent immunoblots for ICAM-2 confirmed t
~30kDa. The “nonspecific” band that appears at ~36kDa in all lanes marked
variants (lanes indicated as + PNGase F) was done to compare relative amo
normalized to the level of actin expression for each cell line. F) ICAM-2 WT
included in Methods. G) Membrane localization of ICAM-2 WT and gsv4,5 w
cells, incubated with an antibody recognizing the extracellular domain (ED
Non-intact cells were gated out using light scatter parameters and propidiu
generated using negative control IgG (blue line) or anti-ICAM-2 (red line). H
variants localized to cell membranes. Experimental details are included in MCell proliferation assays (cell doubling time)
To determine if the growth rates of all SK-N-AS trans-
fectants expressing ICAM-2 variants were comparable,
1×106 cells were plated in 75 cm2 flasks, and cell numbers
determined daily thereafter, using a hemocytometer.
Doubling times were calculated using www.doubling-time.
com/compute.php [27].
Anchorage-independent growth
Each well of a 6-well plate was plated with 1mL 0.8%
Sea-plaque agarose in DMEM with 10% FBS, and cooled
to 4°C overnight. NB cells were resuspended in soft agar
(0.4%) in DMEM with 10% FBS at a density of 30,000
cells in 10 mL, and 1 mL of cell suspension was overlaid
in the wells containing 0.8% agar. Plates were then incu-
bated at 37°C for 14-21 days. Colonies of >20 cells were
























































oteins. A) RNA from control human dermal microvascular endothelial
. All ICAM-2 transfectants contained readily detectable ICAM-2 RNA.
RNA expression levels were within 20% among the transfectants. This
cell lysates (40 μg protein/lane) demonstrated that control HBMEC-28
parent molecular mass of 55-60 kDa. ICAM-2 variants expressed
equivalent levels of actin and α-actinin. D) Deglycosylation of proteins
hat all variants displayed the expected apparent molecular mass of
+ PNGase F is the PNGase F protein itself. E) Quantitation of ICAM-2
unts of ICAM-2 protein expressed by transfectants. Results were
and variants localized to cell membranes. Experimental details are
as confirmed by fluorescence activated cell sorting (FACS) of intact
) of ICAM-2 (CBR-IC2/2) and a PE-conjugated secondary antibody.
m iodide uptake. FACS profiles shown are for PE-positive cells
) Biotinylation experiments also demonstrated that ICAM-2 WT and
ethods.
neo                                            WT
gsv1,4,5    gsv1,2,5
gsv4,5                                     gsv1-6
untransfected
Figure 3 Morphology of ICAM-2 variants derived from SK-N-AS
neuroblastoma cells. Cells plated at low density (~20% confluence) in
CoStar tissue culture flasks were cultured at 37°C at 5% CO2 in humidified
chambers, and allowed to proliferate to ~70% confluence. SK-N-AS cells
transfected to express WT or gsv ICAM-2 have nascent neuronal
morphologies. In comparison to SK-N-ASpIRES.ICAM-2 transfectants (WT),
gsv transfectants were morphologically more pleomorphic and
discohesive. All transfectants grew as attached monolayers. When
detached and sized using a Coulter Counter, no differences in cell size
were observed.
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were included in at least three independent experiments,
as published previously [13,28].
Scratch assays (wound healing assays)
To assess the motility of transfectants expressing ICAM-
2 variants, we performed scratch or wound healing as-
says [29]. Cells were plated at an initial density of 1×106
cells per well in 6-well plates and allowed to grow to
confluency. A centerline was marked on the underside
of each well along its horizontal axis, to designate loci atwhich images would be acquired at each time point.
Vertical linear defects (scratches) were introduced into
cell monolayers using a 200 μL pipet tip. Each well re-
ceived 3 scratches. Images were acquired at 0, 24, 48,
and 72 hours post scratch, at 100× magnification at each
intersection of the scratch wound (vertical defect) and
the marked horizontal centerline using a Dr-5 digital
camera (Southern Microscope) mounted t22232o a
Nikon Eclipse TS100 inverted microscope. For each time
point, 5 measurements were taken per well in each of 3
wells and the average the horizontal width of the linear
defect in pixels calculated using Adobe Photoshop CS4
(version 11.0.2).
Biotinylation of surface proteins
Cells (SK-N-AS cells transfected to express ICAM-2
WT or variants gsv1,4,5; gsv1,2,5; gsv4,5; or gsv1-6) were
plated in 175 cm2 tissue culture flasks (Corning) with
standard growth medium (high glucose DMEM + 10%
FBS + 2 mM L-glutamine) and grown to near-confluence.
Cells were washed 3 times with ice-cold PBS (pH 8.0)
and surface proteins biotinylated for 30 minutes at room
temperature using 0.5 mg/ml EZ-Link® Sulfo-NHS-LC-
Biotin (21335; Thermo Scientific/Pierce) reconstituted in
PBS (pH 8.0). The biotinlyation reaction was quenched
by washing the cells 3 times with 100 mM glycine in
PBS (pH 7.2). Cells were then lysed with 0.5% NP-40 +
complete Mini protease inhibitor (Roche) and homoge-
nized. Biotinylated protein preparations were then incu-
bated with 100 μl Pierce streptavidin® resin (6%
crosslinked beaded agarose 50% aqueous slurry) at room
temperature for 20 minutes with gentle rocking, and
then centrifuged to separate membrane-associated,
biotin-avidin precipitated proteins from unlabeled pro-
teins. After unbound proteins (supernatant) were re-
moved, beads were washed 3 times with cold lysis buffer,
boiled in sample buffer, and subjected to SDS-PAGE.
Following electrophoresis, standard immunoblots were
performed.
Glycosidase digestion
Cleavage of N-linked glycans was carried out using Endo
H (#P0702L; New England BioLabs, Ipswich, MA) and
PNGase F (#P0704S; New England BioLabs, Ipswich,
MA) according to the manufacturer’s instructions. In
brief, 20 μg of protein from control cells (HBMEC-28)
or NB cells expressing ICAM-2 WT or a variant were
denatured at 100°C for 10 minutes with glycoprotein de-
naturing buffer (5% SDS, 0.4M DTT in PBS). After
cooling, protein solutions were centrifuged and incu-
bated for an additional hour at 37°C with 2 μl of either
Endo H enzyme (plus G5 Reaction buffer, pH 5.5; New
England Biolabs) or PNGase F enzyme (plus G7 reaction
buffer, pH 7.5 plus 10% NP-40 ; New England Biolabs).
AB





Figure 4 ICAM-2 WT and glycosylation variants inhibit NB cell migration in scratch assays. Expression of WT and gsv ICAM-2 inhibited
SK-N-AS cell motility in vitro. A) Scratch assays to evaluate cell motility were performed using standard methods, and images acquired at 24 hour
intervals. At each time point, the distance remaining across the scratch was calculated in pixels. Only wells in which initial scratches were of
similar width were included in analyses. B) Analysis by two-way ANOVA followed by Bonferroni post test showed that at 72 hours post scratch, all
variants except gsv4,5 migrated more slowly than transfectants that expressed no detectable ICAM-2 (neo) (P < 0.05* [gsv1-6] and P < 0.001***
[gsv1,4,5 and gsv1,2,5]). At 72 hours post scratch, all gsv transfectants migrated more rapidly than transfectants expressing ICAM-2 WT (P<0.01 –
P<0.001, P values not indicated on graph).
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and digesting conditions, but substituting equivalent vol-
umes of water for enzyme. Samples were then subjected
to SDS-PAGE and immunoblot analyses.
Immunoprecipitations and immunoblots
Co-immunoprecipitations (IP) were done as described
previously [13]. The antibody used for IP of α-actinin
was MAB1682 (Millipore, Fisher Scientific, Savannah,
GA). Antibodies used for immunoblots (IB) for ICAM-2,
α-actinin, and actin were AF244 (R&D Systems, Minne-
apolis, MN) and sc-1512 (Santa Cruz Biotech, Santa
Cruz, CA), 4968 (Cell Signaling Technology, Danvers,
MA), and A5316 (Sigma-Aldrich, St. Louis, MO), respect-
ively. AF244 is a goat polyclonal IgG that recognizes the
extracellular domain of ICAM-2. C-20 is a goat polyclonal
IgG that recognizes the intracellular C-terminus of the
ICAM-2 protein. Secondary HRP-conjugated anti-goat(AF244, sc-1512), anti-rabbit (4968) and anti-mouse
(A5316) antibodies were purchased from Santa Cruz Bio-
tech. The ECL system (Pierce ECL Chemiluminescent
Substrate; Thermo Scientific) was used to detect presence
of horseradish peroxidase (HRP) enzyme. Immunoblot re-
sult in Figure 2D was quantitated using Adobe Photoshop
CS4 (San Jose, CA) by multiplying area by integrated in-
tensity of the band of interest and normalizing that result
to that of a control protein (actin) band.
Subcellular localization of F-actin
Actin fibers were visualized by fluorescence microscopy
using standard methods [30]. Briefly, cells were plated in
chamber well slides (2 × 105 cells per chamber) and
allowed to adhere. Approximately 18 hours after plating,
cells were washed with PBS and fixed with 3.7% (w/v)
paraformaldehyde in PBS for 10 minutes at room
temperature. Remaining attached cells were washed with
gsv1-6                         untransfected





Figure 5 The cellular distribution of F-actin in control
transfectants (neo) differs from that of transfectants expressing
ICAM-2 WT. A) Control neo transfectants harbored transverse actin
fibers. ICAM-2 WT induced juxtamembrane actin fiber distribution.
ICAM-2 gsv expression did not induce a juxtamembrane localization
of actin fibers. Each transfectant was plated at ~60% confluence and
maintained under standard conditions at 37oC to allow the cells to
adhere to chamber slides. Approximately 18 hours after plating, cells
were fixed with 3.7% paraformaldehyde and incubated with FITC-
conjugated phalloidin. Actin fibers were then visualized using
confocal fluorescence microscopy by standard methods. Inset
photomicrographs were acquired at 20x magnification and using a
Zeiss Axio Observer Z.1 microscope platform in conjunction with
Zen 2011 Blue imaging software (Carl Zeiss) (Photomicrographs of
control cell lines (neo and WT) were published previously [13]).
B) The distribution of actin fibers in cells at the leading edge of
migration in scratch (wound healing) assays was similar to actin fiber
distribution in stationary sub-confluent cultures of each cell line.
Scratch assays were performed as described for experiments
depicted in Figure 4. At 72 hours “post scratch”, cells were fixed and
actin fibers visualized using FITC-phalloidin staining as described above,
and fluorescence photomicrographs acquired using Nikon TE2000-U
microscope with X-cite 120 mercury vapor short arc in conjunction
with Q-capture ProV 5.1.1.14 software (Nikon Instruments, Inc.). Care
was taken to acquire images of the control neo transfectants in areas
where residual gaps from the original scratch were still visible, to
confirm acquisition of the leading edge of migration.
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minute. Actin fibers were stained with 10 μg fluorescein
isothiocyanate (FITC)-conjugated phalloidin (P5282;
Sigma-Aldrich, St. Louis, MO) in 1 mL phosphate buff-
ered saline (PBS) for 30 minutes. Phalloidin-stained fibers
were visualized by confocal fluorescence microscope
equipped with narrow band filters, by standard methods
(Figure 5A) or by the Zeiss Axio Observer Z.1 microscope
platform in conjunction with Zen 2011 Blue imaging soft-
ware (Carl Zeiss)(insets in Figure 5A). DAPI (4’,6-
diamidino-2-phenylindole; appears as blue fluorescence)
was used to detect DNA.
Fluorescence-activated cell sorting (FACS)
Flow cytometric analyses were used to verify the cell
membrane localization of ICAM-2 and ICAM-2 vari-
ants. Cells (1 × 106) were trypsinized, washed twice with
PBS, and incubated for 30 min with goat serum (G9023,
Sigma-Aldrich) diluted 1:10 in PBS. Cells were then in-
cubated for 60 minutes on ice with mouse monoclonal
anti-human ICAM-2 antibody (CBR-IC2/2, sc-23935 PE;
Santa Cruz Biotech). A separate aliquot of cells was in-
cubated with mouse isotope-matched IgG (sc-2025,
Santa Cruz Biotech, Santa Cruz, CA) as a negative con-
trol. All samples were then washed twice with FACS buf-
fer (1% BSA in PBS) and incubated for 60 minutes on
ice with phycoerythrin (PE, sc-3798, Santa Cruz Biotech,
Santa Cruz, CA)-conjugated goat anti-mouse IgG. Data
were acquired on an LSR-II cytometer (BD Biosciences,
AB
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Figure 7 ICAM-2 WT and variants co-precipitated with α-actinin.
A) IP/IB experiments with control cell lines demonstrate the expected
association of ICAM-2, α-actinin and actin in lysates from SK-N-ASpIRES.
ICAM-2 cells (labeled as WT), but not SK-N-ASpIRESneo cells (neo).
Results for these control cell lines were published previously [13].
B) ICAM-2 glycosylation site variants associated simultaneously with α-
actinin and actin. Immunoprecipitations (IP) were performed using
whole cell lysates and a mouse monoclonal antibody to α-actinin
(MAB1682, Millipore). Following protein separation by electrophoresis,
immunoblots (IB) were performed with antibodies to α-actinin (sc-
7454, Santa Cruz Biotech), ICAM-2 (AF244, R&D Systems), or actin (4968,
Cell Signaling). The presence of ICAM-2 WT and variants in each
preparation was confirmed by immunoblot analysis of input
preparations (a representative blot is shown in Figure 2C) and also by
immunoblot analysis of the proteins remaining in the supernatant
following precipitation (not shown), to confirm the presence of










































Figure 6 WT and gsv ICAM-2 suppressed anchorage-independent
growth in vitro. All four glycosylation site ICAM-2 variants suppressed
anchorage-independent growth. Soft agar assays were performed
using standard methods. Number of colonies of >20 cells were
visualized 14-21 days after plating and results analyzed using a 2-tailed
t test and GraphPad Prism software. P = 0.0124*. P < 0.0001***. Not
shown in this Figure are control experiments demonstrating that the
growth in soft agar of parental SK-N-AS cells was equivalent to control
SK-N-ASpIRESneo transfectants.
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http://www.biomedcentral.com/1471-2407/13/261San Jose, CA) and analyzed using FlowJo v 7.6.1
(TreeStar) software. Only intact cells, as identified by
forward and side light scatter, were analyzed. Propidium
iodide (5 μg/mL PBS; stored at 4°C in the dark) staining
was also used as a parameter to exclude non-viable cells.
Morphology
Transfected cells were seeded at a density of 15,000
cells/cm2 and maintained under standard culture condi-
tions for 24-48 hours. Photomicrographs were acquired at
20× magnification using a Dr-5 digital camera (Southern
Microscope) mounted to a Nikon Eclipse TS100 inverted
microscope and archived with TSView software (version
7.1.04, Tucsen Imaging Technology Co./Southern Micro-
scope, Inc., Haw River, NC).
Membrane fractionation
Cells were washed three times with PBS at 4°C, and
resuspended in Cell Lysis Buffer (10 mM HEPES, 10
mM NaCl, 1 mM KH2PO4, 5 mM NaHCO3, 1 mM
CaCl2, and 0.5 mM MgCl2 solution ) + 1 mM EDTA +
protease inhibitor (complete mini protease inhibitor tab-
lets; Roche Applied Science, Indianapolis, IN) solution.
Cells were allowed to swell for 5 minutes on ice and
then homogenized using a Fisher Scientific Misonix
XL2000 Ultrasonic Homogenizer (Fisher Scientific), and
centrifuged at 7,500 rpm for 5 minutes. The resulting
supernatant suspension contained both plasmamembrane and cytosolic proteins. This suspension was
then re-centrifuged at 25,000 rpm for 30 minutes to sep-
arate the plasma membrane (pellet) from the soluble
protein fraction. The crude plasma membrane pellet was
then resuspended in 40 μl PBS and standard assays done
to determine the protein concentration of these suspen-
sions. Samples were stored at -80°C until ready for use.
Suspensions were verified as membrane-enriched by im-
munoblot analysis for the plasma membrane marker
(ATP1A1; Novus, Novus Biologicals, Littleton, CO) [31].
Mouse model of metastatic neuroblastoma
Female Es1e/SCID mice (6-8 weeks old) were obtained
from St. Jude Children’s Research Hospital Animal
Figure 8 ICAM-2 variants significantly delayed but did not
completely inhibit development of disseminated tumors in an
in vivo model of metastatic neuroblastoma. Mice received
intravenous injections of SK-N-AS cells expressing no detectable ICAM-2
(neo, N = 10), ICAM-2 WT (N = 10), or one of four hypo-glycosylated
forms of ICAM-2 (N = 5/group). Kaplan-Meier survival plots were
analyzed by log-rank (Mantel-Cox) test using GraphPad Prism 5 software
(Version 5.02). Mice receiving cells expressing hypo-glycosylated ICAM-2
survived longer than mice receiving cells expressing no detectable
ICAM-2, but not as long as mice receiving cells expressing ICAM-2 WT.
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proval of Dr. Phil Potter [32]. The in vivo animal studies
were carried out in accordance with a protocol approved
by the St. Jude Children’s Research Hospital Animal
Care and Use Committee (Approval Number: 374). All
mice were maintained in the Animal Resources Center
at St. Jude and monitored daily for tumor growth. Mice
were euthanized as soon as any animal that appeared to
be in distress or discomfort. Animals were housed in an
AAALAC accredited vivarium at St. Jude Children’s Re-
search Hospital Animal Resources Center under the dir-
ection of Dr. Richard Rahija. Bedding and chow were
autoclaved and cages changed twice weekly.
When injected intravenously into the tail veins of Es1e/
SCID mice, SK-N-AS NB cells (5 × 105 cells) produce dis-
seminated tumors in 100% of mice. The number of cells ad-
ministered was not toxic to Es1e/SCID mice and no
discomfort or death was seen at the time of injection. In this
model, there is no “primary tumor” but the pattern of tumor
development recapitulates the clinical dissemination of
high-risk NB; tumors develop in multiple anatomic locations
including lung, liver and bone marrow [33,34]. Groups of 10
(neo and WT transfectants) or 5 mice (gsv1,4,5; gsv1,2,5;
gsv4,5; gsv1-6 transfectants) were followed for 300 days after
intravenous injection of tumor cells. Any animal that
appeared to be in distress was euthanized and the day of eu-
thanasia was recorded as the day of death.
Statistical analyses
Statistical analyses were performed using GraphPad
Prism software, version 5.02 (GraphPad, San Diego, CA);
graphs were generated using the same software. Two-tailed t tests were used to analyze results of soft agar as-
says and two-way ANOVA followed by Bonferroni post
tests was used to analyze scratch assays. Soft agar assays
and scratch (wound healing) assays were repeated a
minimum of three times, with each experiment includ-
ing six replicates of each cell line. Kaplan Meier survival
data were used to calculate the 95% confidence interval
for time-dependent fractional survival, using a log-rank
(Mantel-Haenszel) test to compare survival of mice re-
ceiving vector control cells (neo), ICAM-2 WT, or gsv
transfected cells.
Results and Discussion
Structural domains of ICAM-2 and ICAM-2 glycosylation
site variants (gsv)
The schematic structure of ICAM-2 (Figure 1) reflects
the complete 275 amino acid glycoprotein. The indicated
domains of this extensively glycosylated protein were
discussed in the Background section. The heavy glyco-
sylation status of the ICAM-2 WT protein dictates its
migration in SDS-PAGE gels as a diffuse band rather than
as a discrete band of specific molecular mass. In this study,
as the degree of glycosylation decreases when glycosyla-
tion sites are mutated, variants are predicted to migrate at
different rates even though the number of amino acids re-
mains unchanged (bottom panel of Figure 1). The non-
glycosylated variant gsv1-6 has a predicted molecular mass
of 30 kDa.
ICAM-2 glycosylation site variants (gsv) localize to cell
membranes in transfected SK-N-AS neuroblastoma cells
SK-N-AS cells express no detectable endogenous ICAM-2
protein [13]. We transfected these cells to stably express
ICAM-2 WT or hypo-glycosylated variants of ICAM-2.
RT-PCR analysis of positive control human dermal vascu-
lar endothelial cells (HDMVEC) and transfectants express-
ing ICAM-2 WT or ICAM-2 glycosylation variants
(gsv1,4,5, gsv1,2,5, gsv4,5 gsv1-6) demonstrated similar
levels of ICAM-2 transcript (Figure 2A, lanes 1,3-7). As
expected, neo transfectants (SK-N-AS cells transfected
with pIRESneo2 control plasmid) (lane 2) expressed no de-
tectable ICAM-2 RNA. Immunoblot analyses (Figure 2C)
done with antibody AF244 (R&D Systems) confirmed pro-
tein expression in all cell lines except SK-N-ASpIRESneo.
Fully glycosylated endogenous ICAM-2 expressed by
HBMEC-28 cells (lane 1) and by transfected ICAM-2 WT
cells (lane 2) migrated in SDS-PAGE gels with the
expected molecular mass of 55-60 kDa [13]. Immunoblots
also demonstrated the expected decrease in apparent
molecular mass of hypo-glycosylated ICAM-2 variants
compared to full length ICAM-2. As the extent of glyco-
sylation decreased, immunoreactive bands appeared less
diffuse and of lower mass. The non-glycosylated variant
expressed by gsv1-6 cells migrated at ~30 kDa, as
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nascent protein – the 21 amino acid signal peptide). Not-
ably, differences in level of glycosylation preclude direct
comparison of levels of protein expression among the
transfectants. Furthermore, the unexpected area/intensity
of the immunoreactive band in the lane containing lysate
from gsv4,5 cells suggest the possibility of N-glycan het-
erogeneity among the differentially glycosylated ICAM-2
variants. Immunoblots for actin and α-actinin served as
loading controls.
Next, we examined ICAM-2 N-glycan sensitivity to
endoglycosidase H (Endo H) and N-glycosidase F (PNGase
F) since modification of glycosylation status can be
detected using these enzymes. Endo H hydrolyzes high
mannose and hybrid N-glycans synthesized in the endo-
plasmic reticulum (ER), while PNGase F hydrolyzes all N-
linked glycans including complex glycans synthesized in
the Golgi. ICAM-2 expressed by all transfectants and
HBMEC-28 cells were sensitive to PNGase F and displayed
increased electrophoretic mobility following a 1 hour incu-
bation with PNGase F (Figure 2D), with non-glycosylated
forms of ICAM-2 migrating at ~30 kDa. (The
“nonspecific” band that appears at ~36kDa in all lanes
marked + PNGase F is the PNGase F protein itself.) In
contrast to results with PNGase F, results following incuba-
tion of cell lysates with Endo H differed for forms of
ICAM-2 that were glycosylated at position 47 compared
with those that were not glycosylated at this position.
ICAM-2 WT and gsv4,5 and ICAM-2 from control
HBMEC-28 cells were Endo H resistant, while gsv1,4,5 and
gsv1,2,5 were Endo H sensitive. Potentially, N-glycans of
ICAM-2 modify protein conformation thereby impacting
protein stability, in addition to their documented roles in
ligand recognition. Comparison of results from gsv4,5 with
gsv1,2,5 and gsv1,4,5 suggests that N-glycans at amino acid
47 may be the most critical with respect to protein con-
formation and stability. Interestingly, quantitation of this
experiment (Figure 2E) by densitometric scanning demon-
strated that the level of gsv1,2,5 expressed was ~60% that
of WT protein and the level of gsv1,4,5 was ~83% that of
WT protein. Possibly this observation reflects a decreased
protein stability of these variants, each of which contained
an amino acid substitution at position 47 that prevented
glycosylation at this site. Further, the robust level of expres-
sion of variant gsv4,5, the only variant that did not contain
an amino acid substitution at position 47, is consistent with
the hypothesis that N-glycosylation at this position may be
critical to ICAM-2 protein structure and stability. Our data
comparing Endo H and PNGase F sensitivities of ICAM-2
WTand variants suggest that N-glycosylation site at amino
acid 47 may be the most critical N-glycan structure with
respect to protein stability.
Next, we showed that similar to the WT protein,
hypo-glycosylated ICAM-2 variants were associated withthe plasma membrane (Figure 2F, 2G, 2H). We first iso-
lated membrane-enriched fractions of each transfectant
and performed immunoblots for ICAM-2 and also for the
plasma membrane marker ATP1A1 (Na+/K+ transporting
ATPase subunit alpha 1; Novus Biologicals, Littleton, CO).
Membrane-enriched fractions contained readily detectable
levels of ATP1A1 and also ICAM-2 proteins of the
expected molecular mass using an antibody that recog-
nizes the CD domain of ICAM-2 (sc-1512; Santa Cruz
Biotech) (Figure 2F). To corroborate these data, we
performed immunofluorescence staining using intact
transfected cell lines and an antibody that recognized the
ED of ICAM-2 (CBR-IC2/2-PE). Flow cytometric analysis
of WT, neo and each of the four gsv transfectants demon-
strated measurable levels of antibody reactivity (cell sur-
face expression in intact cells) for ICAM-2 protein only
for cells expressing WT and gsv4,5 (Figure 2G), even
though gsv1,4,5, gsv1,2,5, and gsv1-6 were clearly seen by
immunoblot. The CBR-IC2/2 antibody was generated
using full length ICAM-2 (Santa Cruz Biotech). This anti-
body recognizes the LFA-1 binding domain of ICAM-2
which includes amino acid residues #42-63 within extra-
cellular IgLD-1 domain [17,35-38], and inhibits binding of
LFA-1 to ICAM-2. Our FACS results show that the CBR-
IC2/2 did not react with any of the three variants
containing an amino acid substitution at position 47
(gsv1,4,5, gsv1,2,5 and gsv1-6), suggesting that substitution
at this position destroyed antibody recognition. However,
since gsv4,5 contained the endogneous Asn at position 47,
we used CBR-IC2/2 to confirm membrane localization of
the expressed variant. The data are consistent with the
previous report [17,35-38] that antibody CBR-IC2/2 rec-
ognizes amino acid residues within IgLD-1 and that an
Asn residue at position 47 is essential for that recognition.
Next, cell surface protein biotinylation was performed
to confirm cell membrane surface localization of all
ICAM-2 variants. As shown in Figure 2H, biotinylation of
proteins of intact cells showed readily detectable ICAM-2
proteins with the expected electrophoretic mobility for all
cell lines. Data in Figures 2F, 2G, and 2H indicate that
ICAM WTand variants localize to cell membranes.
Taken together, the data indicate that variable glycosyl-
ation does not affect the subcellular localization of
ICAM-2 and that variants localize to the plasma mem-
brane similar to the endogenous protein. As expected,
control-transfected SK-N-AS cells showed no detectable
ICAM-2 expression.
Morphology and cell doubling time of transfected gsv
cell lines
Having confirmed expression of transfected cDNAs
and membrane localization of encoded proteins, we
further characterized transfectants with respect to cell
morphology and cell doubling time. Photomicrographs
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cell lines and the untransfected SK-N-AS parent cell line
grow as attached monolayers. In general, all seven also
showed similar nascent neuronal morphology, were simi-
lar in size when detached, and had doubling times of 35.0 ±
4.4 hours. The single exception to this was the gsv1,2,5 cell
line, which had a doubling time of 59 hours. Interestingly,
in spite of being similar in size when detached, the images
in Figure 3 suggest that gsv1,4,5 and gsv1,2,5 transfectants
were more adhesive than the ICAM-2 variant trans-
fectants, and appeared smaller in size when attached and
grew as aggregates more similar to WT transfectants ra-
ther than the more diffuse monolayers of untransfected
and control neo transfectants. In contrast, gsv1-6 trans-
fectants appeared morphologically more similar to neo
controls than to WT transfectants.
Of particular interest, SK-N-ASpIRESneo cells and gsv
transfectants appeared more discohesive and pleomorphic
than cells expressing ICAM-2 WT. Also, SK-N-
ASpIRESneo cells and gsv transfectants had relatively
non-smooth borders compared to cells expressing ICAM-
2 WT. Cells expressing gsv4,5 demonstrated a “drunken
honey comb” appearance, a description frequently appro-
priate to malignant cells with decreased cohesiveness and
non-smooth borders. Cells expressing gsv1-6, grew in
smaller clusters than other transfectants. The most con-
sistent findings were the relatively discohesive and pleo-
morphic characteristics of SK-N-AS cells expressing gsv
transfectants, compared to ICAM-2 WT, possibly indica-
tive of a more motile phenotype than that of cells express-
ing the WT protein.
To address this possibility and to more completely
characterize the functional phenotype of the gsv trans-
fectants, we characterized each transfectant using assays
that reflect specific aspects or cellular functions involved
in metastasis. These assays included cell motility (wound
healing or scratch assays), anchorage-independent
growth in soft agar, subcellular localization of actin fi-
bers (F-actin), and development of disseminated tumors
in an in vivo model of metastatic NB.
ICAM-2 variants altered tumor cell motility but did not
affect actin fiber distribution in vitro
Cell motility is a primary determinant of metastatic po-
tential [39-41]. The actin cytoskeleton, in turn, is a pri-
mary determinant of cell motility. Therefore, we compared
the relative motility of the parental cell line and all six
transfectants in scratch (wound healing) assays (Figures 4A,
4B). We also assessed the subcellular distribution of
F-actin by staining actin fibers with FITC-conjugated
phalloidin (Figure 5A) and the actin fiber distribution of
cells at the leading edge of migration in wound healing as-
says (Figure 5B) to evaluate potential differences between
neo and WT transfectants.First, in standard scratch assays the width of the
scratched area that remained free of cells at 24 hour in-
tervals after introducing the scratch was quantitated in
pixels. Results were expressed as the degree to which the
scratch had closed, at 24 hour intervals post scratch (%
scratch closure). SK-N-ASpIRESneo cells which express
no detectable ICAM-2 completely closed the scratch
within 72 hours (Figure 4A). In contrast, SK-N-AS-
pIRES.ICAM-2 cells migrated more slowly (P < 0.001,
compared to SK-N-ASpIRESneo cells), with only 56% of
the initial scratch filled at 72 hours (Figure 4B). In gen-
eral, cells expressing the gsv ICAM-2 constructs mi-
grated more slowly than control SK-N-ASpIRESneo cells
and more rapidly than SK-N-ASpIRES.ICAM-2 (WT)
cells. P values ranged from < 0.05-0.001 when cell lines
expressing gsv constructs were compared with either
control cell line. The single exception was the lack of a
significant difference in the motility of cells expressing
gsv4,5 and cells expressing no detectable ICAM-2 (neo,
in Figure 4) at any time point. Simple differences in cell
doubling times do not account for the apparent lack of
function (failure to inhibit migration) of gsv4,5, as the
doubling time for these cells did not differ from other
transfectants.
gsv4,5 was the only construct evaluated that did not
contain an Asn → Ala substitution at amino acid 47,
suggesting that glycosylation at this site minimizes or
circumvents the ability of ICAM-2 to inhibit NB cell
motility. Possibly, glycosylation at position 47 inhibits
adhesion, but this effect may be modulated by glycosyla-
tion at other sites in the WT protein. However, since
ICAM-2 WT is glycosylated at this site and the WT pro-
tein significantly inhibits NB cell motility, the data are
not consistent with a straightforward correlation be-
tween glycosylation of this specific residue and cell mo-
tility, as reflected by this assay. The data demonstrate
that NB cell motility was most affected by fully glyco-
sylated ICAM-2, but that three of the hypo-glycosylated
ICAM-2 constructs retained an attenuated function
compared to the endogenous fully-glycosylated protein.
Second, we performed phalloidin staining assays to de-
termine the subcellular distribution of actin fibers. The
ICAM-2-mediated decrease in NB cell motility suggested
a possible involvement of the actin cytoskeletal network, a
primary regulator of cell motility; and our previous work
demonstrated a correlation between transverse distribu-
tion of actin fibers and a relatively motile metastatic
phenotype in a panel of NB cell transfectants. As a prelim-
inary assessment of actin cytoskeletal function, we exam-
ined the subcellular localization of actin fibers in cells
expressing ICAM-2 variants. Fluorescence photomicro-
graphs of F-actin in control cell lines (neo and WT cells in
Figure 5) [13] stained with FITC-conjugated phalloidin
demonstrated the expected contrast in distribution of
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bored transverse actin fibers, while relatively non-motile
SK-N-ASpIRES.ICAM-2 cells had juxtamembrane actin fi-
bers. If the scratch assay and F-actin distribution accur-
ately reflect cell motility, then scratch assay results would
predict that cells expressing gsv4,5 would have transverse
actin fibers and the other three constructs would have
juxtamembrane fibers. FITC-conjugated phalloidin stain-
ing clearly demonstrated that this prediction did not hold
true, and that cells expressing all four ICAM-2 variants
had transverse actin fiber distribution (Figure 5 and data
not shown). This assay does not provide a simple prelim-
inary screen to assess the impact of ICAM-2 WT or gsv
on NB cell motility in vitro.
We then also addressed whether the observed differ-
ences in actin fiber distribution could be attributed to
differences in cell density. We plated neo transfectants
at twice the original density and ICAM-2 cells at half
the original density shown in the insets of the two upper
panels in Figure 5A. Altering cell density did not affect
actin fiber distribution. Actin fiber distribution appeared
to be unrelated to cell density. As an alternative ap-
proach to examine the effect of cell density on F-actin
distribution in the neo and ICAM-2 WT transfectancts
we again performed a scratch assay as shown in Figure 4,
but just prior to complete closure of the scratch by neo
transfectants (~72 hours post scratch), we fixed both
neo and ICAM-2 WT transfectants and incubated the
cells with FITC-conjugated phalloidin. The question to
be addressed was whether the F-actin distribution of
cells at the leading edge of migration would be similar to
its distribution in non-migrating cells. Fluorescence pho-
tomicrographs in Figure 5B show that both non-migrating
and migrating SK-N-ASpIRESneo cells display transverse
actin fibers and both non-migrating and migrating SK-N-
ASpIRES.ICAM-2 cells display juxtamembrane actin
fibers.
All four ICAM-2 variants inhibited colony growth in
anchorage-independent growth assays
We next assessed anchorage-independent colony growth
in vitro, an assay that often reflects tumorigenic poten-
tial in vivo in preclinical models. Of note, while some-
what controversial, multiple published studies have also
demonstrated correlations between growth in soft agar
and metastatic, rather than tumorigenic potential
[42-44]. Our previously published data demonstrate that
ICAM-2 transfectants with decreased metastatic poten-
tial in vivo also produce fewer colonies in soft agar
in vitro [13]. A plausible explanation consistent with ob-
served correlations between anchorage-independent
growth in vitro and metastatic potential in vivo is that
relatively motile cells show decreased sensitivity to loss
of anchorage dependency and therefore a greatercapacity to initiate colony growth. The aggregation of
sparsely plated cells precedes colony growth, and cells
that more readily aggregate (relatively motile cells) pro-
duce more viable colonies in soft agar. Therefore, it was
of interest to determine whether hypo-glycosylated
ICAM-2 variants suppressed growth in soft agar to the
same extent as ICAM-2 WT. As expected, cells express-
ing fully-glycosylated ICAM-2 WT formed fewer col-
onies in soft agar (9.6 ± 1.4) than control transfectants
(227 ± 10.1 colonies) (P< 0.0001***, Figure 6). The num-
ber of colonies produced by all variants was intermediate
to the number of colonies produced by cells expressing
the WT and cells expressing no detectable ICAM-2.
Hypo- and non-glycosylated variants produced signifi-
cantly fewer colonies than control transfectants (P <
0.0001), but significantly more colonies than SK-N-AS-
pIRES.ICAM-2 cells (P < 0.05 - < 0.0001). The single ex-
ception to this observation was that cells expressing
gsv4,5 produced the similar number of colonies (16.7 ±
2.6) as SK-N-ASpIRES.ICAM-2 cells. Hypo-glycosylated
ICAM-2 suppressed anchorage-independent growth, but
the degree of suppression was less than that induced by
ICAM-2 WT. We concluded that all forms of ICAM-2
were functional in this assay, and that the cells express-
ing each of the four variants needed to be characterized
using an in vivo model of metastatic NB.
ICAM-2 WT and all four variants associate with α-actinin
and actin
Prior to undertaking these in vivo experiments, we
addressed a more mechanistic aspect of ICAM-2 func-
tion in NB cells. Our previous work demonstrated that
the α-actinin binding site in the cytoplasmic domain
(CD) of ICAM-2 is essential to ICAM-2-mediated sup-
pression of disseminated tumor development in an
in vivo model of metastatic NB [13]. When the α-actinin
binding site of ICAM-2 is intact, ICAM-2 associates
with α-actinin and actin simultaneously and suppresses
the metastatic properties of NB cells. Having observed
that the four gsv transfectants retained the function of
the WT protein in either scratch or anchorage-
independent growth assays or both, we postulated that
the glycosylation status of ICAM-2 would not affect its
association with α-actinin and actin in NB cells. To ad-
dress this hypothesis, we performed immunoprecipita-
tions (IP) with an antibody to α-actinin, and then
immunoblots (IB) to determine whether gsv ICAM-2
variants associated with α-actinin and actin. IP/IB results
for positive (WT) and negative (neo) control cell lines
(Figure 7A) demonstrate the anticipated interaction of
ICAM-2, α-actinin and actin compared to minimal
interaction of α-actinin and actin when ICAM-2 was not
expressed. IP/IB results (Figure 7B) showed that all
ICAM-2 variants associated with α-actinin and actin.
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are qualitative and do not necessarily reflect the ratio in
which these proteins associate for several reasons.
Firstly, immunoblots for glycosylated ICAM-2 give an
area x density signal approximately 300% - 400% greater
than that for the same amount of de-glycosylated
ICAM-2 (Figure 2C). Secondly, α-actinin induces actin
self-association [45], resulting in variable numbers of
actin molecules associated with a single α-actinin mol-
ecule. Thirdly, the necessary use of mono- and poly-
clonal antibodies likely allows binding of secondary
antibodies to a variable number of recognition sites on
primary antibodies. However, the data do clearly indicate
that all four variants associate with α-actinin, an inter-
action essential to ICAM-2-mediated suppression of
metastatic potential. Based on this mechanistic consider-
ation and on cell function assays (Figures 4 and 6), we
would predict that all hypo-glycosylated ICAM-2 vari-
ants retain at least partial function, in suppressing meta-
static properties of NB cells. Next, we tested this
hypothesis in a murine model of metastatic NB. Of note,
based on co-IP data in Figure 7, ICAM-2 WT and gsv4,5
appear to interact more readily with α-actinin than do
the other three hypo-glycosylated ICAM-2 variants. We
next evaluated the function of ICAM-2 WT and variants
in an in vivo model of metastatic neuroblastoma.
Hypo- and non-glycosylated ICAM-2 delay tumor
progression in a preclinical model of metastatic
neuroblastoma
To determine the extent to which N-linked glycosylation
impacts the metastatic phenotype of ICAM-2 expressing
NB cells in vivo, we injected each of the SK-N-AS NB
cell transfectants intravenously into 6-8 week old Es1e/
SCID mice, and observed the mice for tumor develop-
ment. As expected, Kaplan-Meier survival plots demon-
strated that mice receiving control cells (N = 10) that
express no detectable ICAM-2 (Figure 8, neo [solid red
line]) developed tumors at multiple anatomic sites and
required euthanasia within 2-3 months. Also as
expected, mice receiving cells that express ICAM-2 WT
(N = 10) developed no tumors and survived significantly
longer (300 days, P < 0.001 compared to controls). Inter-
estingly, expression of hypo-glycosylated ICAM-2 de-
layed, but did not prevent, development of disseminated
tumors in this in vivo model. More specifically, when
mice were injected with control neo transfectants, tu-
mors became evident by non-invasive imaging within
30-60 days (data not shown). Euthanasia of mice in this
group was required as early as day 38. In contrast, mice
injected with gsv4,5 transfectants did not develop detect-
able tumors or require euthanasia until day ~200. At day
300, the termination date of the experiment, no tumor
was evident in a subset of this group of mice. Thesimilarity in function of WT and gsv4,5 in anchorage-
independent growth assays (Figure 6), interaction with α-
actinin (Figure 7), and the in vivo survival assay (Figure 8)
suggest the hypothesis that glycosylation of ICAM-2 at
amino acid 47 contributes significantly to the function of
ICAM-2 in NB cells. However, overall, mice receiving cells
expressing each of the glycosylation site variants survived
longer than control cells (P ≤ 0.0002), but not as long as
mice receiving cells expressing ICAM-2 WT (P ≤ 0.05).
Hypo-glycosylation attenuated but did not abolish the
ability of ICAM-2 to suppress metastatic properties of NB
cells.
Conclusions
While in vitro cell motility (scratch assay) most accur-
ately predicted cell phenotype in vivo, no single in vitro
assay consistently predicted results in vivo for all ICAM-
2 variants. In general, the morphology, anchorage-
independent growth, and motility of cells expressing
hypo- or non-glycosylated variants of ICAM-2 were
intermediate to characteristics of negative and positive
control transfectants expressing no detectable ICAM-2
or the WT protein. In vivo results for all transfectants
were also intermediate to these control cell lines, in that
expression of gsv transfectants significantly delayed but
did not prevent the occurrence of disseminated disease
in a model of metastatic NB. In addition, our results
from Endo H sensitivity studies suggest that glycosyla-
tion at position 47 may be critical to protein folding or
conformation, and that glycosylation at this position
likely affects protein stability. Potentially, a decrease in
ICAM-2 protein stability leads to lower levels of
membrane-associated ICAM-2, which, in turn, impacts
the novel role of ICAM-2 in suppressing metastatic
properties. We conclude that the glycosylation status of
ICAM-2 significantly affects the function of this protein
in SK-N-AS NB cells.
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